You will receive a Shipment Confirmation email once your order has shipped containing your tracking number(s). The tracking number will be active within 24 hours. We offer return or exchange of ...
You will receive a Shipment Confirmation email once your order has shipped containing your tracking number(s). The tracking number will be active within 24 hours. Customs, Duties and Taxes: We are not ...
Key market opportunities in the PLC sector include the shift to software-defined automation, driven by Industry 4.0 adoption and demand for modular architectures in large plants. Asia-Pacific leads ...
Deals: Boehringer Ingelheim agreed to a pact with Simcere Pharmaceutical that could be worth approximately $1.26 billion. Eli Lilly announced it will work with startup Seamless Th ...
The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...
Global drugmakers are ramping up US manufacturing and stockpiling inventory as the Trump administration considers a 100 per ...
The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of around 20% during the forecast ...
Trialbee to Share Vision for the Last Mile of Patient Recruitment with Expert Panel, AI Innovation, and Community Collaboration at SCOPE Summit 2026 Featuring panelists from BMS, Biogen, and Johnson & ...
Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those taking GLP-1 receptor agonists.
11d
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, ...
Biogen BIIB announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results